Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...

US pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...

Production Linked Incentive schemes, which aim to boost manufacturing and attract significant investments, have disbursed Rs 35,354 crore t...

India's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 CY2026, with volumes falling 17% quarter-on-quarter to a f...

Sun Pharmaceutical Industries Ltd announced shareholder approval for its Organon & Co acquisition. This significant milestone moves the pro...

US President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export sign...

A U.S.-India trade agreement is nearing completion and could be signed soon. Negotiations are virtually finished, with only U.S. trade inve...

Food processing leads PLI employment, creating jobs with minimal investment. Electronics manufacturing attracted significant capital but ge...

The healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...

President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...

The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one...

Hikal has commissioned an enhanced cGMP pilot plant at its Pune campus to strengthen its integrated capabilities for pharmaceutical develop...

For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...

Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...